ALISO VIEJO, Calif., March 09, 2017 (GLOBE NEWSWIRE) -- NVISION Eye Centers – a national leader in ophthalmic treatments and services, is pleased to announce the introduction of Avedro Photrexa® Viscous, Photrexa® and the KXL System used in corneal collagen cross-linking for the treatment of keratoconus. The procedure has the ability to both stabilize and strengthen the cornea, halting or slowing the progression of keratoconus in the early phases of the condition. It can also improve vision in some patients with a more progressed stage of the condition.
“Keratoconus is a progressive thinning and distortion of the cornea that can result in significant visual loss and may lead to the need for a corneal transplant.” states Dr. Tom Tooma, founder of NVISION Eye Centers. “NVISION surgeons are treating patients who are suffering from progressive keratoconus. We are excited to offer a long term solution to our patients with this condition.”
The announcement follows the recent approval that Avedro, Inc., an ophthalmic pharmaceutical and medical device company, has received from the U.S. Food and Drug Administration (FDA).
ABOUT NVISION EYE CENTERS: NVISION Eye Centers is one of the largest providers of LASIK and cataract surgery in the U.S., with 26 centers in California, Nevada, Oregon, Arizona and Toronto, Canada. An innovative leader in ophthalmology, NVISION is dedicated to providing the best patient experience through the use of the latest technology and treatment by the most talented and experienced surgeons in the industry. NVISION was founded in 2010 by Tom Tooma, M.D., one of the earliest pioneers of LASIK who has performed more than 100,000 procedures throughout his esteemed career. With more than 1,900 eye doctors referring their patients and trusting their own eyes to NVISION surgeons, NVISION Eye Centers is the Eye Doctors' #1 Choice®. For more information, visit www.NVISIONCenters.com or call (877) 455-9942.